We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$409M 8.49%
6,244,451
-1,608,747
-20% -$78.5M
ARGX icon
2
argenx
ARGX
$53.8B
$403M 8.37%
546,328
-24,711
-4% -$16.3M
RVMD icon
3
Revolution Medicines
RVMD
$39.6B
$260M 5.41%
5,573,838
+994,538
+22% +$38.9M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$248M 5.14%
1,763,105
-56,895
-3% -$7.71M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$204M 4.23%
446,524
-229,843
-34% -$93.6M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$123B
$198M 4.12%
505,805
+64,195
+15% +$26.8M
ABT icon
7
Abbott
ABT
$175B
$198M 4.11%
1,478,563
-85,459
-5% -$11.2M
SYK icon
8
Stryker
SYK
$123B
$167M 3.46%
451,096
-83,993
-16% -$32.5M
BSX icon
9
Boston Scientific
BSX
$65.4B
$162M 3.37%
1,659,849
-105,345
-6% -$10.9M
ISRG icon
10
Intuitive Surgical
ISRG
$122B
$156M 3.24%
348,626
-30,102
-8% -$14.4M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$149M 3.1%
3,714,736
+124,586
+3% +$4.69M
INCY icon
12
Incyte
INCY
$23.4B
$122M 2.54%
1,440,686
-129,647
-8% -$10.2M
SRRK icon
13
Scholar Rock
SRRK
$6.33B
$121M 2.51%
3,244,537
+297,242
+10% +$10.4M
AKRO
14
DELISTED
Akero Therapeutics
AKRO
$113M 2.36%
2,389,314
+404,042
+20% +$19.6M
IMCR icon
15
Immunocore
IMCR
$1.78B
$102M 2.11%
2,796,803
+354,973
+15% +$12.1M
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$93.8M 1.95%
+2,152,862
New +$87M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.77B
$92M 1.91%
3,557,669
+250,100
+8% +$5.8M
MDT icon
18
Medtronic
MDT
$106B
$72.4M 1.5%
759,861
-161,182
-17% -$14.8M
BEAM icon
19
Beam Therapeutics
BEAM
$2.83B
$70.1M 1.46%
2,889,288
– –
EW icon
20
Edwards Lifesciences
EW
$49.4B
$69.7M 1.45%
896,633
+7,556
+0.8% +$590K
PODD icon
21
Insulet
PODD
$11.4B
$65.5M 1.36%
212,005
-7,008
-3% -$2.2M
UNH icon
22
UnitedHealth
UNH
$387B
$58.7M 1.22%
170,057
+27,761
+20% +$8.4M
BDX icon
23
Becton Dickinson
BDX
$43.6B
$55.6M 1.15%
296,894
-19,838
-6% -$3.69M
DXCM icon
24
DexCom
DXCM
$29.6B
$52.9M 1.1%
786,118
-74,710
-9% -$5.91M
TMO icon
25
Thermo Fisher Scientific
TMO
$198B
$51.5M 1.07%
106,185
-7,359
-6% -$3.43M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.